Description
(AWP Alliance News) - The following stocks are the leading risers and fallers in Europe's major stock indices on Tuesday.
----------
CAC 40 WINNERS
----------
STMicroelectronics NV, up 1.8% at EUR41.21
----------
Schneider Electric SE, up 1.6% at EUR239.40
----------
EssilorLuxottica SA, up 1.5% at EUR177.60
----------
CAC 40 LOSERS
----------
Renault SA, down 2.3% at EUR25.60
----------
Stellantis NV, down 1.8% at EUR3.62
----------
Pernod Ricard SA, down 1.8% at EUR66.48
----------
DAX 40 WINNERS
----------
Siemens Energy AG, up 1.6% at EUR125.18
----------
SAP SE, up 1.2% at EUR214.75
----------
Infineon Technologies AG, up 1.0% at EUR50.71
----------
DAX 40 LOSERS
----------
Mercedes-Benz Group AG, down 4.3% at EUR39.60, cuts profit guidance
----------
Beiersdorf AG, down 4.0% at EUR79.74, Nivea weighs on earnings
----------
Volkswagen AG, down 2.1% at EUR67.86
----------
FTSE 100 WINNERS
----------
Rentokil Initial PLC, up 2.2% at 347.10p
----------
Antofagasta PLC, up 1.9% at 3,233.00p, Deutsche Bank raises to 'hold' from 'sell'
----------
Rio Tinto PLC, up 1.4% at 6,327.50p
----------
FTSE 100 LOSERS
----------
HSBC Holdings PLC, down 7.0% at 1,269.60p, profit shy of consensus
----------
Reckitt Benckiser Group PLC, down 4.3% at 5,250.00p, cuts annual outlook
----------
Burberry Group PLC, down 2.3% at 1,042.50p
----------
MIB 40 WINNERS
----------
Snam Spa, up 2.5% at EUR6.14
----------
STMicroelectronics, up 2.1% at EUR41.36
----------
Italgas Spa, up 2.0% at EUR8.91
----------
MIB 40 LOSERS
--------------------
Stellantis NV, down 1.5% at EUR3.64
----------
Campari NV, down 1.4% at EUR6.64
----------
A2A Spa, down 1.0% at EUR2.41
----------
SMI 20 WINNERS
----------
Novartis AG, up 1.7% at CHF129.62, raises outlook
----------
Holcim Ltd, up 0.6% at CHF67.30
----------
Amrize Ltd, up 0.7% at CHF32.79
----------
SMI 20 LOSERS
----------
Galderma Group AG, down 0.9% at CHF189.10
----------
Sandoz Group AG, down 0.8% at CHF81.72
----------
Logitech International SA, down 0.7% at CHF90.58
----------
European stock movers in focus:
----------
HSBC Holdings, down 7.0% at 1,269.60p, 12-month range 979.80p-1,610.00p. The Asia-focused, London-based bank says pretax profit jumped 32% to USD9.63 billion in the three months ended September 30 from USD7.30 billion a year earlier. Profit falls just short of company-compiled consensus of USD9.70 billion. HSBC maintains its third-quarter dividend at USD0.10 per share and announces plans for a new USD1 billion share buyback programme, which it aims to complete by its 2026 results.
----------
Mercedes-Benz Group, down 4.3% at EUR39.60, 12-month range EUR38.89-EUR62.34. The Stuttgart, Germany-based carmaker cuts its annual guidance, now seeing earnings before interest and tax "at the prior-year level" of EUR5.82 billion. It previously expected an outcome "significantly above" this. "In addition to an increasingly challenging market environment in China, Mercedes-Benz Group expects higher costs in the fourth quarter, including higher material costs," the carmaker explains. It releases earnings for the third quarter on Wednesday.
----------
Beiersdorf, down 4.0% at EUR79.74, 12-month range EUR67.08-EUR110.15. The personal care products company says third quarter group sales rise 0.4% to EUR2.36 billion, but decline 1.3% organically. Net sales at Nivea alone slide 4.9%. "Nivea continued to be impacted by temporary sell-in headwinds," Beiersdorf says.
----------
Novartis, up 1.7% at CHF129.62, 12-month range CHF97.05-CHF132.68. It lifts its annual profit guidance despite a fall in third-quarter profit, partly due to a near USD2 billion hit from a disappointing drug trial result. The pharmaceutical company says net income in the third quarter of 2026 plunges 70% to USD1.20 billion from USD3.93 billion a year prior. At constant currency, the fall is 71%. Net sales, however, are 4.4% higher a USD14.52 billion from USD13.91 billion. Constant currency sales growth is 4%, the Basel, Switzerland-based firm says. Higher research and development expenses keep a lid on profit, including a USD1.9 billion partial impairment charge related to the del-desiran asset. Novartis now sees low single-digit core operating income growth for the full year. Its prior view was for a low-single-digit percentage decline. Core operating income in 2025 rose 12% to USD21.89 billion. In the third quarter, core operating income is 11% higher on-year at USD6.04 billion. The core profit measure excludes one-off items, so the UD1.9 billion del-desiran impairment is not included.
----------
By Eric Cunha, Alliance News news editor
Comments and questions to newsroom [at] alliancenews.com
Copyright 2026 Alliance News Ltd. All Rights Reserved.
